Tyra Biosciences Inc. has disclosed new indazole compounds acting as fibroblast growth factor receptor (FGFR) inhibitors. They are reported to be useful for the treatment of cancer and developmental disorders.
China Pharmaceutical University has prepared and tested sphingomyelin phosphodiesterase (SMPD1; aSMase) inhibitors potentially useful for the treatment of cancer, autoimmune disease, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, depression, diabetes, hepatic steatosis and stroke, among others.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety. They are reported to be useful for the treatment of cancer.
Merna Therapeutics Inc. has discovered polypeptides targeting sortilin (neurotensin NTR3; NT3; Gp95) receptor. They are reported to be useful for the treatment of cancer.
Nanjing Anji Biotechnology Co. Ltd. has patented micropeptides regulating cholesterol metabolism and thus reported to be useful for the treatment of obesity, atherosclerosis, age-related macular degeneration, hyperlipidemia, fatty liver, liver fibrosis, liver cancer and coronary heart disease, among others.
The Institut National De La Santé et de la Recherche Médicale, Université de Bordeaux and Université de Paris Cité have synthesized N-phenyl-quinoline-4-carboxamide compounds acting as furin (PACE; PCSK3) inhibitors. They are reported to be useful for the treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising antibodies targeting cadherin-3 (CDH3; CDHP; P-cadherin) covalently linked to cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
RSS